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Background: CervarixTM (GlaxoSmithKline), AS04 adju-
vanted cervical cancer vaccine, has been shown to be
safe, immunogenic and highly effective for the pre-
vention of persistent human papillomavirus (HPV)-16/18
infection and associated precancerous lesions in girls and
women aged 15—25 years. Since many countries recom-
mend HPV vaccination in adolescents when other pediatric
and adolescent vaccines are routinely administered, co-
administration of CervarixTM with other vaccines will
be convenient for physicians and vaccinees. This study
(108464/NCT00426361) evaluated the immunogenicity and
safety of CervarixTM co-administered with BoostrixTM Polio
(dTpa-IPV, GlaxoSmithKline) a diphtheria-tetanus-acellular
pertussis-inactivated polio vaccine. Methods: Healthy girls
aged 10—18 years were randomized in 3 groups to
receive either HPV-16/18 vaccine alone (HPV-16/18 group;
n = 248), HPV-16/18 co-administered with dTpa-IPV (HPV-
16/18+dTpa-IPV group; n = 252), or dTpa-IPV vaccine alone
(n = 251). Immunogenicity (ATP) and safety were assessed 1
month after the ﬁrst vaccine dose.
Results: Interim data on immunogenicity and safety 1
month after the ﬁrst dose are presented. Co-administration
of HPV-16/18 and dTpa-IPV was demonstrated non-inferior
to separate administration of dTpa-IPV, with seropro-
tection rates of 99.6% for anti-diphtheria and 100%
for anti-tetanus antibodies in both groups. Seropositiv-
ity rates for anti-pertussis and seroprotection rates for
anti-poliovirus type antibodies were ≥98.7% and 100%,
respectively, in the HPV-16/18+dTpa-IPV group and ≥96.5%
and ≥99.6% in the dTpa-IPV group. Seroconversion rates
for anti-HPV 16 and 18 antibodies in initially seroneg-
ative subjects were 100% in the HPV-16/18 group and
99.1% in the HPV-16/18+dTpa-IPV group. Post-vaccination
GMTs in HPV-16/18+dTpa-IPV group were similarly high as
for respective antigens in the HPV-16/18 and dTpa-IPV
groups. Co-administration of the two vaccines was gener-
ally well-tolerated. No subjects withdrew due to adverse
events and no vaccine-related serious adverse events were
reported.
Conclusion: Results from this interim analysis show that
the co-administration of CervarixTM with BoostrixTM Polio
does not affect the immune response to each individual
vaccine, and is well-tolerated.
doi:10.1016/j.ijid.2008.05.372
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Cholera is a diarrheal disease caused by toxigenic Vibrio
cholerae belonging to O1 and O139 serogroups. Cholera epi-
demics can be prevented in the future if there is a common
vaccine which gives protection for both the serogroups, O1
and O139. However currently available vaccine gives pro-
tection only for O1 and do not cross protect cholera caused
by O139. Hence, this study was focused to develop a biva-
lent (O1 and O139) ALA auxotropic vaccine candidates. Using
genetic engineering techniques we have developed ALA aux-
otrophs of O139 and O1 V. cholerae by mutating the hemA
gene and were named VCUSM2 and VCUSM4 respectively. The
live bivalent formulation of VCUSM2 and VCUSM4 was tested
in animal models for colonization ability, reactogenicity,
immunogenicity and protection. Infant mouse colonization
assay showed that the bivalent vaccine candidates colonized
well but the colonization ability was 1 log lower than the
parent wild type strains. Reactogenicity of bivalent vaccine
candidates were studied using rabbit ileal loop assay and
showed reduced ﬂuid accumulation when compared to the
respective wild type strains. When ileal loop assay was car-
ried out in the immunized animals with 105 CFU of WT O1 and
O139 strains no ﬂuid accumulation was seen, indicating that
the bivalent vaccine candidate elicited cholera toxin (CT)
neutralizing antibodies. However the unimmunized animals
showed marked ﬂuid accumulation at the same concentra-
tion. This was further substantiated by the presence of high
titer of vibriocidal antibodies (500—1000 fold), anti CT anti-
bodies (5—20 fold) and anti LPS (O1 and O139) antibodies
after 4 weeks of immunization. Bivalent vaccine provided
100% protection in RITARD model when challenged with
either O1 or O139 virulent wild types V. cholerae. These
results demonstrated that the bivalent vaccine is highly
immunogenic with minimal reactogenicity at high CFU and
provides protection against O1 and O139 serogroups of V.
cholerae.
doi:10.1016/j.ijid.2008.05.373
